ICYMI: Amgen’s Whiny Attempt to Fight Lower Drug Costs Denied in Court

The Decision Is a Win for Affordability, Loss for Corporate Greed

RICHMOND, Va. — Last month, a U.S. District Court Judge ruled in favor of the Colorado Prescription Drug Affordability Board, dismissing Pharmaceutical giant Amgen’s suit that claimed the company would suffer economic injuries as a result of upper payment limits determined by the Board on their commonly used drug Enbrel.

Judge Nina Y. Wang ruled that Amgen had not been able to show that it had or will suffer from economic damage like it claimed in its suit, saying “The economic injuries alleged by Amgen are too speculative and too attenuated to support standing in this case.”

Freedom Virginia co-Executive Director Rhena Hicks released the following statement regarding the decision:

“This decision is a major win for states across the country looking to establish a Prescription Drug Affordability Board (PDAB). The drug at the center of the suit was Enbrel, an autoimmune disease treatment that produced $3.3 billion in revenue for Amgen last year. This frivolous lawsuit proved one thing: pharmaceutical companies are more concerned with losing profits than helping patients. Lowering the cost of medicine should not be controversial. All people, whether Coloradans or Virginians, should not have to choose between groceries, rent, and the medicine they need. We’re excited to continue monitoring the Colorado PDAB’s progress and will continue to fight for affordable medicine here in Virginia.”

Enbrel has consistently been one of Virginia’s most expensive prescription drugs, ranking as the fifth most burdensome drug to the Virginia state budget. According to Virginia Health Information, Enbrel cost Virginia over $81 million in 2023, making it the sixth most costly drug for commercial coverage. And in 2024, Amgen spent over $50,000 to lobby against Prescription Drug Affordability Board legislation in Virginia.

The Virginia Prescription Drug Affordability Board legislation, despite building on momentum from 2024 and passing both chambers of the General Assembly with bipartisan support again this year, was recently vetoed by Governor Glenn Youngkin. The Board would allow Virginia to set upper payment limits on certain high-cost drugs like Enbrel, lowering the burden on the state and patients.

Picture of Natalie Jones

Natalie Jones

Help get the word out by sharing

Related

Youngkin’s Veto Blocks Progress on Lower Medicine Costs

Freedom Virginia Applauds Bipartisan Supporters of Bill to Lower Medicine Costs, Will Continue Pushing Bill in Future RICHMOND, Va. — Freedom Virginia today applauded the bipartisan majority of senators who attempted to override Governor Glenn Youngkin’s